AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24479280 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruity tea
Number of subjects: 6
Study 24479280 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea
Number of subjects: 6
Study 24479280 — intervention group
Group type: EXPERIMENTAL
Intervention: Floral tea
Number of subjects: 6
Study 24479280 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea
Number of subjects: 6
Study 22153519 — intervention group
Group type: EXPERIMENTAL
Intervention: Menhaden oil (DHA and EPA)
Number of subjects: 12
Study 22153519 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil (control)
Number of subjects: 12
Study 19944875 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapleson‐C manual hyperinflation circuit
Number of subjects: 12
Study 19944875 — intervention group
Group type: COMPARATOR
Intervention: Magill manual hyperinflation circuit
Number of subjects: 12
Study 16686557 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity strength training
Number of subjects: 59
Study 16686557 — intervention group
Group type: COMPARATOR
Intervention: Stretching and aerobic exercising
Number of subjects: 59
Study 16686557 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive strength training
Number of subjects: 59
Study 15295415 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive medical therapy
Number of subjects: 728
Study 15295415 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary revascularization
Number of subjects: 728
Study 11764421 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-wedge osteotomy hemicallotasis (HCO)
Number of subjects: 50
Study 11764421 — intervention group
Group type: COMPARATOR
Intervention: Conventional high tibial osteotomy (DMO)
Number of subjects: 50
Study 9236641 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (Partocon 10 IU)
Number of subjects: 1000
Study 9236641 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (0.9%)
Number of subjects: 1000
Study 11767422 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% nitrous oxide in oxygen
Number of subjects: 100
Study 11767422 — intervention group
Group type: COMPARATOR
Intervention: 100% oxygen
Number of subjects: 100
Study 3661527 — intervention group
Group type: EXPERIMENTAL
Intervention: 34-item food frequency instrument
Number of subjects: 37
Study 3661527 — intervention group
Group type: EXPERIMENTAL
Intervention: Limiting the instrument to top 15 foods
Number of subjects: 37
Study 3661527 — intervention group
Group type: EXPERIMENTAL
Intervention: Limiting the instrument to top 10 foods
Number of subjects: 37
Study 3661527 — intervention group
Group type: EXPERIMENTAL
Intervention: Limiting the instrument to top 5 foods
Number of subjects: 37
Study 3661527 — intervention group
Group type: EXPERIMENTAL
Intervention: Rating all portions as 'medium'
Number of subjects: 37
Study 3661527 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-item instrument (rating portion sizes in ounces or cups)
Number of subjects: 37
Study 29426359 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric handgrip (IHG) home training (30% of maximum grip strength for a total of 8 min per day per hand) three times a week for 20 weeks
Number of subjects: 50
Study 29426359 — intervention group
Group type: COMPARATOR
Intervention: Usual care (hypertension guidelines on lifestyle changes)
Number of subjects: 50
Study 26419735 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental Reminiscence Intervention‐Hong Kong (IRI‐HK)
Number of subjects: 114
Study 26419735 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 114
Study 25917814 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-month supervised multimodal exercise program (n = 56), 60 minutes once a week at moderate intensity (3.84-4.84 MET-hour)
Number of subjects: 85
Study 25917814 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group, n = 29)
Number of subjects: 85
Study 23605469 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of olanzapine 10 mg
Number of subjects: 24
Study 23605469 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of olanzapine 10 mg
Number of subjects: 24
Study 23605469 — intervention group
Group type: COMPARATOR
Intervention: Test vs. Reference formulation
Number of subjects: 24
Study 20949850 — intervention group
Group type: EXPERIMENTAL
Intervention: 210 ms movement time
Number of subjects: 40
Study 20949850 — intervention group
Group type: COMPARATOR
Intervention: 350 ms movement time
Number of subjects: 40
Study 18444130 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein isolate (SPI+)
Number of subjects: 58
Study 18444130 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-washed soy protein (SPI-)
Number of subjects: 58
Study 18444130 — intervention group
Group type: COMPARATOR
Intervention: Milk protein (MPI)
Number of subjects: 58
Study 18444130 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 58
Study 18444130 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy groups (SPI+ and SPI-)
Number of subjects: 58
Study 16952205 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.75 mg midazolam
Number of subjects: 28
Study 16952205 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.25 mg midazolam
Number of subjects: 28
Study 15561831 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin at 750 mg once daily plus metronidazole at 500 mg every 8 hours
Number of subjects: 18
Study 15561831 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin at 750 mg once daily plus metronidazole at 1,500 mg every 24 hours
Number of subjects: 18
Study 15561831 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin at 750 mg once daily plus metronidazole at 1,000 mg every 24 hours
Number of subjects: 18
Study 11451294 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 2457
Study 11451294 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive strategy
Number of subjects: 2457
Study 9084068 — intervention group
Group type: EXPERIMENTAL
Intervention: THA 25 mg
Number of subjects: 19
Study 9084068 — intervention group
Group type: EXPERIMENTAL
Intervention: THA 50 mg
Number of subjects: 19
Study 8273571 — intervention group
Group type: EXPERIMENTAL
Intervention: Azapropazone (APZ) 600 mg b.i.d.
Number of subjects: 40
Study 8273571 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (IND) 50 mg t.i.d.
Number of subjects: 40
Study 8273571 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (NAP) 500 mg b.i.d.
Number of subjects: 40
Study 8273571 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam (PIR) 20 mg qq.d.
Number of subjects: 40
Study 8273571 — intervention group
Group type: COMPARATOR
Intervention: Placebo (C)
Number of subjects: 40
Study 3315584 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary streptokinase (20,000U bolus, then 2000 U/minute)
Number of subjects: 93
Study 3315584 — intervention group
Group type: EXPERIMENTAL
Intervention: APSAC (30U over 2 to 4 minutes)
Number of subjects: 93
Study 3315584 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 93
Study 3315584 — intervention group
Group type: EXPERIMENTAL
Intervention: APSAC
Number of subjects: 93
Study 30938014 — intervention group
Group type: EXPERIMENTAL
Intervention: CARE protocol training
Number of subjects: 49
Study 27811072 — intervention group
Group type: EXPERIMENTAL
Intervention: Early adenotonsillectomy (n=182)
Number of subjects: 353
Study 27811072 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting with supportive care (WWSC) (n=171)
Number of subjects: 353
Study 27811072 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resolution of OSAS (based on apnoea-hypopnoea index)
Number of subjects: 353
Study 27811072 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous normalisation of apnoea-hypopnoea index
Number of subjects: 353
Study 26220093 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-incision phacotrab
Number of subjects: 49
Study 26220093 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification
Number of subjects: 49
Study 24617278 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone support groups (15 groups of 5 or 6 caregivers), met 14 times over 1 year, 1-hour sessions including education, coping skills, and support
Number of subjects: 154
Study 24617278 — intervention group
Group type: COMPARATOR
Intervention: Control group (print materials)
Number of subjects: 154
Study 21392067 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-734200 20 mg/day
Number of subjects: 289
Study 21392067 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-734200 30 mg/day
Number of subjects: 289
Study 21392067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study 19139778 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 60
Study 19139778 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 60
Study 19139778 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 17223873 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical methylaminolaevulinate (MAL) photodynamic therapy (PDT)
Number of subjects: 8
Study 17223873 — intervention group
Group type: COMPARATOR
Intervention: Topical 5% fluorouracil (5‐FU) cream
Number of subjects: 8
Study 15346824 — intervention group
Group type: EXPERIMENTAL
Intervention: Close phototherapy (15 cm above the patient)
Number of subjects: 98
Study 15346824 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote phototherapy (30‐45 cm above patient)
Number of subjects: 98
Study 15346824 — intervention group
Group type: COMPARATOR
Intervention: Control group (incubator patients)
Number of subjects: 98
Study 11394510 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.05 mg x kg(‐1) (PM; n = 13)
Number of subjects: 24
Study 11394510 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (PO; n = 11)
Number of subjects: 24
Study 9766818 — intervention group
Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunts (TIPS)
Number of subjects: 5
Study 9766818 — intervention group
Group type: COMPARATOR
Intervention: Paracentesis
Number of subjects: 5
Study 7880512 — intervention group
Group type: EXPERIMENTAL
Intervention: Subarachnoid bupivacaine blockade (12.5 mg)
Number of subjects: 53
Study 7880512 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular saline (control)
Number of subjects: 53
Study 7880512 — intervention group
Group type: COMPARATOR
Intervention: Intravenous midazolam (control)
Number of subjects: 53
Study 3367388 — intervention group
Group type: EXPERIMENTAL
Intervention: 252Cf therapy
Number of subjects: 65
Study 3367388 — intervention group
Group type: COMPARATOR
Intervention: 137Cs therapy
Number of subjects: 65
Study 29333561 — intervention group
Group type: COMPARATOR
Intervention: Venetoclax (10-500 mg single doses and 30-600 mg multiple doses)
Number of subjects: 73
Study 29333561 — intervention group
Group type: COMPARATOR
Intervention: Venetoclax
Number of subjects: 73
Study 29333561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 27313280 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR with self-expanding bioprosthesis
Number of subjects: 747
Study 27313280 — intervention group
Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 747
Study 27313280 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 747
Study 25088029 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol-enriched protein powder (PSPC) 40 g/day for 17 days
Number of subjects: 0
Study 25088029 — intervention group
Group type: COMPARATOR
Intervention: Placebo (soy protein and colorings)
Number of subjects: 0
Study 25088029 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol-enriched protein powder (PSPC)
Number of subjects: 0
Study 22913893 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive intervention based on single-pill amlodipine/atorvastatin (SPAA) 5/10 to 10/20 mg
Number of subjects: 600
Study 22913893 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) based on investigators' best clinical judgment
Number of subjects: 600
Study 22913893 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive intervention based on SPAA
Number of subjects: 600
Study 22913893 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 600
Study 20825669 — intervention group
Group type: EXPERIMENTAL
Intervention: e-learning condition (three digital learning modules about alcohol, tobacco, and marijuana over three school years)
Number of subjects: 3784
Study 20825669 — intervention group
Group type: EXPERIMENTAL
Intervention: integral condition (parental participation and monitoring in addition to the e-learning modules)
Number of subjects: 3784
Study 20825669 — intervention group
Group type: COMPARATOR
Intervention: control condition (business as usual)
Number of subjects: 3784
Study 18469568 — intervention group
Group type: EXPERIMENTAL
Intervention: Braced condition (neoprene knee sleeve)
Number of subjects: 64
Study 16018384 — intervention group
Group type: EXPERIMENTAL
Intervention: TEP laparoscopic hernioplasty
Number of subjects: 60
Study 16018384 — intervention group
Group type: COMPARATOR
Intervention: Bassni inguinal hernia repair
Number of subjects: 60
Study 12852710 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g of PLT 3514 emulsion (0.75 g GLA + 0.5 g EPA)
Number of subjects: 47
Study 12852710 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g of PLT 3514 emulsion (1.5 g GLA + 1 g EPA)
Number of subjects: 47
Study 12852710 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g of PLT 3514 emulsion (7.5 g GLA + 5 g EPA)
Number of subjects: 47
Study 12852710 — intervention group
Group type: COMPARATOR
Intervention: Placebo emulsion containing olive oil
Number of subjects: 47
Study 10390662 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimenhydrinate (62 mg IV after induction, repeated three times during 48 hours)
Number of subjects: 133
Study 10390662 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline, repeated three times during 48 hours)
Number of subjects: 133
Study 10390662 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimenhydrinate
Number of subjects: 133
Study 10390662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 8888596 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy mood
Number of subjects: 0
Study 8888596 — intervention group
Group type: COMPARATOR
Intervention: Neutral mood
Number of subjects: 0
Study 8888596 — intervention group
Group type: EXPERIMENTAL
Intervention: Sad mood
Number of subjects: 0
Study 8888596 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy mood with secondary task
Number of subjects: 0
Study 8888596 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy mood with small script-inconsistent information
Number of subjects: 0
Study 8888596 — intervention group
Group type: EXPERIMENTAL
Intervention: Sad mood with secondary task
Number of subjects: 0
Study 1802054 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment regimes without bone grafting
Number of subjects: 85
Study 1802054 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment regimes including bone grafting at 10 years of age
Number of subjects: 85
Study 1802054 — intervention group
Group type: EXPERIMENTAL
Intervention: Group receiving bone grafts at 6 months after presurgical orthopaedics
Number of subjects: 85
Study 1802054 — intervention group
Group type: EXPERIMENTAL
Intervention: Group receiving bone grafts after the eruption of the incisors but before the eruption of the canines
Number of subjects: 85
Study 6404440 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat inactivated hepatitis B virus vaccine (3 micrograms HBsAg)
Number of subjects: 800
Study 6404440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study 6404440 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat inactivated hepatitis B virus vaccine
Number of subjects: 800
Study 31665039 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based cognitive rehabilitation (CR) program with psychological support for 8 weeks, consisting of three 45-minute sessions per week using PRESCO® software.
Number of subjects: 40
Study 31665039 — intervention group
Group type: COMPARATOR
Intervention: Psychological support only, addressing everyday cognitive-related difficulties and management of emotions.
Number of subjects: 40
Study 31665039 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based cognitive rehabilitation (CR) program with psychological support for 8 weeks.
Number of subjects: 40
Study 31665039 — intervention group
Group type: COMPARATOR
Intervention: Psychological support only.
Number of subjects: 40
Study 29879143 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (0.1, 1, 3, or 5 mg/kg) administered every 28 days for 2 or 4 doses
Number of subjects: 24
Study 27379733 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP4 inhibitors
Number of subjects: 295
Study 27379733 — intervention group
Group type: COMPARATOR
Intervention: Other antidiabetic therapies
Number of subjects: 295
Study 25257633 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 2211
Study 25257633 — intervention group
Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 2211
Study 22661628 — intervention group
Group type: EXPERIMENTAL
Intervention: Isis (squeeze-handle mechanism)
Number of subjects: 0
Study 22661628 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmony (squeeze-handle mechanism)
Number of subjects: 0
Study 22661628 — intervention group
Group type: COMPARATOR
Intervention: Little Heart (cylindrical mechanism)
Number of subjects: 0
Study 22661628 — intervention group
Group type: COMPARATOR
Intervention: Evenflo (cylindrical mechanism)
Number of subjects: 0
Study 20801248 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with LBP
Number of subjects: 48
Study 20801248 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 48
Study 20801248 — intervention group
Group type: EXPERIMENTAL
Intervention: All subjects
Number of subjects: 48
Study 20801248 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with LBP and Healthy controls
Number of subjects: 48
Study 19098657 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of Cefotaxime at the moment of gallbladder rupture, followed by 2 more doses at intervals of 8 hours in the immediate postoperative period
Number of subjects: 166
Study 19098657 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic treatment
Number of subjects: 166
Study 16243241 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 38
Study 16243241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 12848773 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg clarithromycin twice daily for 3 days
Number of subjects: 12
Study 12848773 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous digoxin with oral clarithromycin
Number of subjects: 12
Study 10577448 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol succinate (CR/XL)
Number of subjects: 60
Study 10577448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 8718540 — intervention group
Group type: COMPARATOR
Intervention: Conventional cartilaginous incisions
Number of subjects: 1164
Study 8718540 — intervention group
Group type: EXPERIMENTAL
Intervention: Modification of cartilaginous incisions
Number of subjects: 1164
Study 8718540 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques of cartilaginous incision
Number of subjects: 1164
Study 1868679 — intervention group
Group type: COMPARATOR
Intervention: Temazepam 20 mg
Number of subjects: 12
Study 1868679 — intervention group
Group type: COMPARATOR
Intervention: Temazepam 10 mg
Number of subjects: 12
Study 1868679 — intervention group
Group type: COMPARATOR
Intervention: Temazepam 5 mg
Number of subjects: 12
Study 1868679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7079903 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 15-(S)-15-methyl-PGF2 alpha
Number of subjects: 30
Study 7079903 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intra-uterine extra-amniotic infusion of 15-(S)-15-methyl-PGF2 alpha
Number of subjects: 30
Study 30789856 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole 10 mg
Number of subjects: 390
Study 30789856 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilaprazole 5 mg
Number of subjects: 390
Study 30789856 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilaprazole 10 mg
Number of subjects: 390
Study 30789856 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 390
Study 28434798 — intervention group
Group type: COMPARATOR
Intervention: Standard radiochemotherapy (stdRT) (70Gy/35 fractions)
Number of subjects: 25
Study 28434798 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose escalation (DE) (77Gy/35 fractions) to hypoxic volumes (HV)
Number of subjects: 25
Study 28434798 — intervention group
Group type: COMPARATOR
Intervention: Standard radiochemotherapy (stdRT)
Number of subjects: 25
Study 27146475 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Person‐Based Cognitive Therapy (PBCT) and Treatment As Usual (TAU)
Number of subjects: 108
Study 27146475 — intervention group
Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 108
Study 27146475 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Person‐Based Cognitive Therapy (PBCT)
Number of subjects: 108
Study 24529582 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 25 mg/day for 1 week followed by 50 mg/day for 3 months
Number of subjects: 60
Study 24529582 — intervention group
Group type: COMPARATOR
Intervention: Behavioral Therapy (BT) for 3 months
Number of subjects: 60
Study 22807627 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi
Number of subjects: 102
Study 19179739 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord serum screening test measuring total serum IgE, Der p1, Blo t5, and g IFN levels
Number of subjects: 100
Study 19179739 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 100
Study 17475584 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 140
Study 17475584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 15337334 — intervention group
Group type: EXPERIMENTAL
Intervention: Concordance Therapy
Number of subjects: 19
Study 15337334 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 19